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was considered as efﬁcient (a=10% b=10%)), the secondary criteria
were: the results at 24 months for arthroscopy, histology, MRI, and the
evaluation of the surgical technique.
Treatment: Biopsy of 200 to 300mg of cartilage from a non bearing
zone of the knee, cellular expansion and incubation in an agarose
and alginate hydrogel with manufacturing of 10, 14 or 18mm diameter
implants distributed in the lesion.
Results: 20 patients have been included, 17 have been implanted, (a
chondrocalcinosis, a culture failure, a ﬁbrocartilage reconstruction have
not been implanted). Patients characteristics: Average age: 30 years old,
12 Men/5 Women, 10 OD, Average IKDC initial score: 37, Average lesions’
surface 3 cm2. Mean criterion: IKDC at 24 months: 77.8 (p 3 cm2, and
almost signiﬁcant for OD and grade 4 lesions. MRI: 10 patients on 15 pre-
sented an identical signal/normal cartilage, for 11 patients/15 no visible
transition. Arthroscopies: 13 realized with an average ICRS score of 10 on
12. Histology: O’Driscoll Average score on 21: 16. 8 patients presented
a mostly hyaline cartilage, 3 a mixed hyaline and 1 ﬁbrocartilage. The
average surgery time was 41 minutes.
Conclusions: The cartilage graft in a CARTIPATCH® hydrogel conﬁrms
a signiﬁcant clinical improvement especially for deep and large lesions.
The use of a matrix allowing a homogeneous distribution and no cellular
leakage can explain the good histological results with over 60% of the
repaired cartilage mostly hyaline at 24 months. Two phase III studies one
versus osteochondral autografts and one versus microfracture have been
started.
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505 EFFECTS OF JOINT LAVAGE IN PATIENTS WITH
OSTEOARTHRITIS OF THE KNEE: META-ANALYSIS OF
RANDOMIZED CONTROLLED TRIALS
J. Avouac, T. Bardin, P. Richette. Hoˆpital Lariboisie`re, Paris, FRANCE
Purpose: To assess the clinical relevance of joint lavage alone or com-
bined with intraarticular steroid injection to improve pain and function in
osteoarthritis (OA) of the knee.
Methods: A systematic literature search was performed in electronic
databases (Medline, Embase and Cochrane database) up to April 2008.
References of the papers were hand searched to identify additional rele-
vant reports. There was no language restriction. All randomized controlled
trials (RCTs) performed on patients with knee OA with parallel groups
and evaluating either (1) the efﬁcacy of joint lavage alone versus placebo
or (2) joint lavage combined with steroid injection versus joint lavage
alone, were selected. Efﬁcacy was evaluated on pain intensity (pain
visual analogic scale [VAS], Western Ontario and Mac master universities
Osteoarthritis index [WOMAC] subscale for pain or pain on movement
VAS) and physical function (WOMAC function or Lequesne’s functional
index). The time point for evaluation was a priori decided and ﬁxed at three
months. Effect sizes were calculated using RevMan to compare results
across studies. We used the standardized mean difference (change from
baseline pain or function at 3 months) as our measure of effect size for
each study.
Results: From the 334 articles identiﬁed, seven RCTs (four studies
analyzed joint lavage versus placebo, and three joint lavage with steroid
injection versus joint lavage alone) were included and analyzed, i.e. a total
of 1009 patients (582 in the active group and 427 in the control group).
The median (min-max) value of the journals’ impact factor in which were
published the different trials was 5.78 (3.06−51.3) and the mean (SD)
Jadad score was 3.5 (1.5). The pooled effect sizes of joint lavage versus
placebo were not signiﬁcant for pain intensity (ES=−0.02 [−0.21, 0.17])
(ﬁgure 1) and physical function (ES=−0.16 [−0.35, 0.03]). The pooled
effect sizes of joint lavage combined with steroid injection versus joint
lavage alone were also not signiﬁcant for pain intensity (−1.24 [−1.49,
−0.99]) or physical function (ES=0.09 [−0.28, 0.45]).
Conclusions: This meta-analysis suggests that at three months (i) joint
lavage alone does not provide signiﬁcant improvement in pain or function
over placebo, (ii) combination of lavage and intraarticular steroid injection
is no more efﬁcacious than lavage alone.
506 COMBINATION OF TWO HYALURONIC ACIDS IN
OSTEOARTHRTITS OF THE KNEE.
R.J. Petrella, J. DeCaria, A. Cogliano. U Western Ontario, London, ON,
CANADA
Purpose: Patients may alternate between different hyaluronic acid prod-
ucts and experience different degrees of efﬁcacy. This may be the result
of differing molecular weight needs within the synovial ﬂuid of patients
through the course of their osteoarthritis symptoms.
Methods: To compare the efﬁcacy and safety of different molecular
weight hyaluronic acid alone or in combination in patients with osteoarthri-
tis of the knee we conducted a randomized, prospective, double blind
cohort followed for 16 weeks in which patients were randomized at
baseline to receive a three intra-articular injection series with one of:
DMW (Dual molecular weight) (580–780 kDa + 1.2 to 2.0 million); LMW
(Low molecular weight) (500–730 kDa); HMW (High molecular weight)
(6 million); or saline placebo over 3 weeks. Patients completed baseline
assessment of rest and walking VAS pain (primary efﬁcacy variable),
collection of a 5-point categorical global satisfaction score and record of
adverse events.
Results: Two-hundred and twenty-ﬁve patients (age 68±8 y) were
screened and two hundred were randomized to one of the four groups.
There were no differences at baseline between groups. At 4, 12 and
16 weeks respectively, walking VAS pain was signiﬁcantly improved
in all treatment groups vs Placebo: DMW (79.6%, p< 0.001; 85.6,
p< 0.001; 89.3%, p< 0.001); LMW (73.6%, p< 0.001; 76.4, p< 0.001;
81.3%, p< 0.001) and HMW (69.1%, p< 0.001; 81.0, p< 0.001; 79.1%,
p< 0.001). Patients in the DMW group had signiﬁcantly greater improve-
ment (p< 0.007) in VAS walking pain by three weeks (following the
second injection) compared to all groups. This difference was persistent
to 16 weeks.
Conclusions: Greater improvement in patients who received the DMW
product was achieved by the second injection persistent at 16 weeks. This
suggests that patients who receive a combination of molecular weight
hyaluronic acid may have superior results.
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Purpose: International recommendations (EULAR) about managing knee
osteoarthritis support the concomitant use of medications and non-
pharmacological treatments. The aim of this clinical survey was to de-
termine practice patterns among general practitioners (GPs) in France
regarding non-pharmacological treatments in patients with recurrent or
persistent pain from knee osteoarthritis.
Methods: Survey among GPs. No support was received from pharma-
ceutical companies. Each GP completed a questionnaire about the ﬁrst
patient seen for recent pain exacerbation due to known knee osteoarthri-
tis. The questionnaire collected the main clinical symptoms, in order
to distinguish mechanical pain from an inﬂammatory osteoarthritis ﬂare
(nocturnal pain and synovial ﬂuid effusion), and the non-pharmacological
treatments prescribed at the end of the visit based on the clinical mani-
festations.
Results: 638 questionnaires were completed; women contributed 70% of
the patients, mean age was 66 years and mean BMI was 28 kg/m2; both
knees were affected in 50% of patients. A limp was the most common
symptom (82%); mechanical pain was noted in 75% and joint effusion in
37% of patients. Nocturnal pain with a joint effusion was present in 12%
of patients.
Overall, 30.9% of GPs recommended rest and 36.5% reducing walking.
Rest was recommended by 50% of GPs for patients with nocturnal
pain and joint effusion (ﬂare) compared to 20% for patients with neither
symptom. Although EULAR guidelines recommend regular exercise in
the absence of ﬂares, only 34.5% of GPs prescribed physical therapy.
Surprisingly, physical therapy was prescribed more often in patients with
ﬂares (46%) than without ﬂares (33.4%). Most GPs (66.6%) recom-
mended a weight-reduction diet. Using a cane was recommended by
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29.6% of GPs, insoles by 8.4%, and a knee brace by 3.7%. At least one
non-pharmacological treatment was recommended by 88.1% of GPs.
Conclusions: Although most GPs in France used non-pharmacological
treatment in combination with drugs to treat patients with persistent pain
from knee osteoarthritis, the choice of non-pharmacological measures
was not always appropriate to the clinical proﬁle. Efforts are needed to
improve the use by GPs of non-pharmacological treatments in patients
with knee osteoarthritis.
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Purpose: To investigate the effectiveness of multidisciplinary outpatient
rehabilitation program (MRP), implemented 2−4 months after primary to-
tal knee arthroplasty (TKA), on functional recovery, health related quality
of life (HRQoL), and rehabilitation service utilization.
Methods: In the prospective, randomized, controlled trial a total of 88
participants were scheduled for TKA due to osteoarthritis (OA) of the
knee. Participants (n = 86) were randomized on the day of their discharge
after surgery to a control group (usual orthopedic care) or an active
group (additional 10-day MRP). Each MRP course consisted of up to 8
participants. The aim of the MRP was to improve participants’ coping with
the activities of daily living, including improvement of lower-limb strength,
increase of lower-limb joint mobility, improvement of endurance and
cardiovascular ﬁtness, and reinforcement of coping strategies. Further
objectives were motivating the participants to carry out a regular exercise
program, and weight control or weight reduction. The ﬁnal aim of the MRP
was psychosocial recreation, especially through peer support.
Assessments of both groups, performed preoperatively, and at the 2,
6, and 12-month follow-ups, included questionnaires [the Western On-
tario and McMaster Universities OA Index (WOMAC), the 15D and the
RAND 36-Item Health Survey 1.0 (RAND-36)] and physical performance
measures [15-meter (m) walk test, stair test, and isometric strength
measurement of the knee]. The use of rehabilitation services was asked
by means of a self-administered questionnaire. Response to the treatment
was analyzed at the 12 month-follow-up according to the guidelines of the
Outcome Measures in Rheumatology-Osteoarthritis Research Society
International (OMERACT-OARSI). The mixed model approach was used
to analyze repeated measurements. Pt∗g indicates time-group interaction.
Figure 1. Results of the WOMAC scores (Median and 25th-
75thpercentiles) preoperatively and at the 2, 6, and 12-month follow-ups.
Results: Self-reported disability and pain declined, objectively measured
physical performance, and HRQoL improved signiﬁcantly in both groups.
No difference was found between groups in any outcome measure during
the study period. The results of the WOMAC scores are presented in
Figure 1. In the 15D score participants in both groups reached the level
of the general public of the same age at the 12-month follow-up. The
absolute change in 3 physical domain scales of the RAND-36 (PF, BP
and RP) during the study period was 20 in both groups, indicating sig-
niﬁcant clinical improvement. Remarkable improvement, which plateaued
at 6 months, was found in the results of all physical performance tests. No
difference was found between groups in the use of additional postopera-
tive rehabilitation services (p = 0.77). According to the OMERACT-OARSI
criteria high improvement was detected in 26 (72.2%) participants of the
AG, and in 27 (69.2%) participants of the CG at the 12-month-follow-up.
Conclusions: The MRP 2−4 months after TKA did not yield faster
attainment of functional recovery than did standard orthopedic care alone.
Dramatic improvement in functional ability, pain, HRQoL, and physical
performance was gained in both groups within the ﬁrst 6 months after
surgery.
509 BIOCOMPATIBILITY AND PROTEIN RECOGNITION STUDIES
OF DUROLANETM, A HYALURONAN HYDROGEL
S. Johansson1, M. Olson2, A. Kultti3, M. Tammi3, R. Tammi3. 1Q-Med
AB, Uppsala, SWEDEN, 2Bow Valley Research, Calgary, AB, CANADA,
3Department of Anatomy, University of Kuopio, FINLAND
Purpose: In the synovial ﬂuid (SF) of patients suffering from osteoarthritis
(OA) a decrease in the concentration and in the molecular weight of
hyaluronan can be observed. Therefore, treatment of OA includes intra-
articular injections of hyaluronan whereby the viscoelastic properties
of the SF are believed to be restored. During the past years it has,
however, become evident that the mechanism of action of intra-articular
injections of hyaluronan may be more than this; important interactions with
hyaluronan binding proteins and receptors may be involved. For this to
take place, the injected product needs to be recognized as hyaluronan by
the body. Current hyaluronan products for OA treatment include solutions
of puriﬁed hyaluronan as well as hyaluronan hydrogels, where the material
has been crosslinked into networks. Some of the hydrogels have been
suggested to be less biocompatible than others, which may depend on
e.g. the source and purity of the ingoing material. In addition, the chemical
structure of the crosslinked polysaccharide and thus the ability of the body
to recognise it as hyaluronan may vary substantially.
In the present study, (i) the biocompatibility of DurolaneTM in the joint
and (ii) the ability of proteins that bind hyaluronan with high speciﬁcity,
to interact with Durolane in vitro, has been investigated. Durolane is
composed of hyaluronan of bacterial origin that has been crosslinked
into a network by Q-Meds patented NASHATM manufacturing process.
The product has the appearance of a clear gel composed of small gel
particles.
Methods: Biocompatibility; Durolane was injected into the knee of anes-
thetized rabbits. This was repeated after 6 and 12 weeks (a total of three
injections). The animals were observed for adverse events, and knee joint
capsules were sectioned and studied microscopically.
Protein interactions; A complex (containing the hyaluronan binding Link
module) was puriﬁed from cartilage and labelled with Alexa-Fluor® 594
(HABCﬂ). Durolane gel particles were incubated at room temperature in
PBS containing 75mg/ml of HABCﬂ and viewed by confocal microscopy.
Probe pre-incubated with hyaluronan oligosaccharides was used as a
negative control. The degradation of Durolane by hyaluronidase was
monitored by the use of ultra ﬁltration and detection of released hyaluronic
acid (HA) oligomers using carbazole. A solution of hyaluronan of the
same concentration was degraded at the same time and by the same
conditions, as a reference.
Results: Biocompatibility studies revealed no evidence of inﬁltration of
inﬂammatory cells, necrosis, irritation or any deleterious inﬂammatory
reactions within the joint capsule and within the surrounding tissue. In the
confocal microscope, particles of Durolane appeared strongly ﬂuorescent
after incubation with HABCﬂ. The speciﬁc nature of the interaction was
conﬁrmed by the negative controls which were devoid of ﬂuorescence. In
the hyaluronidase assay, Durolane exhibited the same degradation proﬁle
as the solution of hyaluronan.
Conclusions: Durolane appears to be safe and without adverse reactions
when used for intra-articular injections. In addition, the gel could be
recognised by proteins containing the LINK module conferring normal
hyaluronan binding. Thus hyaluronan present in Durolane can interact
with hyaluronan binding proteins and is likely to confer the same signals
as endogenous hyaluronan.
